文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

基于直线加速器的分次立体定向放疗与立体定向放射外科治疗最多十处脑转移瘤的可行性

Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases.
PubMed 文献 · Radiat Oncol · 2022-12-28

这项回顾性队列研究纳入了2016年7月至2018年6月在同一机构连续接受直线加速器fSRT或SRS的176例1-10处脑转移瘤患者,按转移灶数量分为1处(78例)、2-4处(67例)、5-10处(31例)三组。5-10处组与2-4处组在总生存、局部控制、颅内远处失败和放射性坏死方面相当,作者认为对5-10处脑转移瘤患者使用fSRT和SRS似乎是合理的。

要点

  • 5-10处组与2-4处组在OS、LC、DIF和RN方面相当。
  • 1处组较2-4处组OS显著更优(HR 0.59,95%CI 0.40-0.87;p=0.0075)。
  • 2级及以上放射性坏死发生于21例(13.5%),未观察到4级和5级。

核心结论

  • 对5-10处脑转移瘤患者行直线加速器fSRT和SRS,其OS、LC、DIF和RN与2-4处患者相当。
  • 作者认为对5-10处脑转移瘤患者使用直线加速器fSRT和SRS似乎是合理的。

研究设计与样本

  • 这是一项回顾性队列研究,收集2016年7月至2018年6月在同一机构连续接受fSRT或SRS的1-10处脑转移瘤患者数据。
  • 排除既往接受全脑放疗、同期使用全脑放疗或手术切除的患者,共176例纳入分析。
  • 按脑转移瘤数量分为三组:1处组78例、2-4处组67例、5-10处组31例。
  • 采用Kaplan-Meier法估计总生存曲线,采用竞争风险累积发生率估计局部控制、颅内远处失败和放射性坏死。

主要发现

  • 1处组、2-4处组、5-10处组的中位OS分别为19.8个月(95%CI 10.2-27.5)、7.3个月(95%CI 4.9-11.1)、5.1个月(95%CI 4.0-9.0)。
  • 与2-4处组相比,1处组OS显著更优(HR 0.59,95%CI 0.40-0.87;p=0.0075)。
  • 与2-4处组相比,5-10处组OS相当(HR 1.36,95%CI 0.85-2.19;p=0.199)。
  • 肿瘤数量组间LC、DIF和RN无显著差异,但1处组DIF较低。
  • 2级及以上放射性坏死发生于21例(13.5%),未观察到4级和5级放射性坏死。

关键数值与推荐

  • 中位OS:1处组19.8个月(95%CI 10.2-27.5),2-4处组7.3个月(95%CI 4.9-11.1),5-10处组5.1个月(95%CI 4.0-9.0)。
  • 1处组 vs 2-4处组OS的HR为0.59(95%CI 0.40-0.87;p=0.0075)。
  • 5-10处组 vs 2-4处组OS的HR为1.36(95%CI 0.85-2.19;p=0.199)。
  • 2级及以上放射性坏死21例(13.5%),未观察到4级和5级放射性坏死。

临床怎么用

  • 原文结论认为对5-10处脑转移瘤患者使用直线加速器fSRT和SRS似乎是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linac-based fractionated stereotactic radiotherapy (fSRT) and stereotactic radiosurgery (SRS) are increasingly being used to manage patients with multiple metastases. This retrospective cohort study aimed to compare the outcomes after linac-based fSRT and SRS between three patient groups classified based on the number of brain metastases (BMs): 1 BM, 2-4 BM, 5-10 BM. METHODS: The data of consecutive patients with 1-10 BMs treated with fSRT or SRS between July 2016 and June 2018 at a single institution were collected. Patients with previous whole-brain radiotherapy (WBRT), concurrent use of WBRT, or surgical resection were excluded from the analysis. A total of 176 patients were classified into three groups according to the number of BMs: 78, 67, and 31 patients in 1 BM, 2-4 BM, and 5-10 BM, respectively. The Kaplan-Meier method was used to estimate overall survival (OS) curves, and the cumulative incidence with competing risks was used to estimate local control (LC), distant intracranial failure (DIF), and radiation necrosis (RN). RESULTS: Median OS was 19.8 months (95% confidence interval [CI] 10.2-27.5), 7.3 months (4.9-11.1), and 5.1 months (4.0-9.0) in 1 BM, 2-4 BM, and 5-10 BM, respectively. Compared to 2-4 BM, 1 BM had significantly better OS (hazard ratio [HR] 0.59, 95% CI 0.40-0.87; p = 0.0075); however, 5-10 BM had comparable OS (HR 1.36, 95% CI 0.85-2.19; p = 0.199). There was no significant difference in LC, DIF, and RN between tumor number groups, but DIF was lower in 1 BM. RN of grade 2 or higher occurred in 21 patients (13.5%); grade 4 and 5 RN were not observed. CONCLUSIONS: The linac-based fSRT and SRS for patients with 5-10 BMs is comparable to that for patients with 2-4 BMs in OS, LC, DIF, and RN. It seems reasonable to use linac-based fSRT and SRS in patients with 5-10 BMs.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hirata M, Yasui K, Oota N, et al. Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases. Radiat Oncol. 2022. PMID: 36578021. doi:10.1186/s13014-022-02185-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。